I'm mystified too Raj. I've yet to do a full analysis of what has been reported but at a glance WH has continued to grow, particularly Nextstellis, this is pleasing given that we have a new sales team and leadership. Dermatology revenue is disappointing but it could just be a seasonal issue, time will tell. Underlying EBITDA now A$14.7M , on track for possibly over A$60M given the commentary for the FY25 (we did A$22.9 in FY24) and underlying cashflow of A$16.1M (excludes class action settlement). More later. We are now trading at less than 1 multiples of sales revenue (typical is 4) and 6X EBITDA (typical is 18)
MYX Price at posting:
$4.18 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)